Prism Medico and Pharmacy Ltd Stock Price Today (NSE: PRISMMEDI)
Prism Medico and Pharmacy Ltd
Fundamental Score
Prism Medico and Pharmacy Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Prism Medico and Pharmacy Ltd share price today is ₹25.21, up +1.61% on NSE/BSE as of 30 March 2026. Prism Medico and Pharmacy Ltd (PRISMMEDI) is a Small-cap company in the Non Banking Financial Company (NBFC) sector with a market capitalisation of ₹11.21 (Cr). The 52-week high for PRISMMEDI share price is ₹30.22 and the 52-week low is ₹12.07. At a P/E ratio of 18.38x, PRISMMEDI is currently trading below its industry average P/E of 22.03x. The company has a Return on Equity (ROE) of -0.33% and a debt-to-equity ratio of 0.00.
Prism Medico and Pharmacy Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Prism Medico and Pharmacy Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Prism Medico and Pharmacy Share Price: A ROCE Efficiency Analysis
In the Non-Banking Financial Company (NBFC) sector, a crucial, often overlooked, dynamic is the disproportionate impact of operating leverage on smaller players. While large NBFCs possess robust cost structures, smaller entities are far more vulnerable to fluctuations in interest rates and operating expenses. This analysis examines the implications for Prism Medico and Pharmacy share price, currently trading at ₹18.450001 with a Price-to-Earnings (PE) ratio of 18.38. A core element of our evaluation focuses on the company’s Return on Capital Employed (ROCE).
Prism Medico and Pharmacy Ltd's ROCE stands at a concerning -0.4%. ROCE, a key metric for evaluating profitability relative to capital employed, signals how efficiently a company utilizes its capital to generate profits. A negative ROCE indicates that the company is not generating sufficient returns to cover the cost of its capital. This directly impacts the company’s “moat,” or its competitive advantage. A low or negative ROCE makes it difficult to reinvest in growth, defend market share, or attract further investment.
Considering its peers, a comparative analysis reveals potential challenges for Prism Medico. While a full peer comparison requires further data, a focus on management quality is pertinent. For example, comparing Prism Medico and Pharmacy Ltd with
Apollo Finvest, one might consider publicly available information regarding their leadership teams, strategic decisions, and corporate governance practices. These factors can significantly influence investor confidence and long-term performance. Differences in management quality can translate to varying levels of operational efficiency and risk management, ultimately impacting ROCE.The -0.4% ROCE raises questions about the sustainability of Prism Medico and Pharmacy Ltd's current business model. Without significant improvement in capital efficiency or profitability, the company may face difficulties in funding future growth and maintaining its competitive position within the NBFC sector. A turnaround strategy focusing on cost reduction, revenue enhancement, and optimized capital allocation could be crucial. This observational analysis, part of an 80-parameter fundamental audit verified by Sweta Mishra, aims to provide insights into the financial health and efficiency of Prism Medico and Pharmacy Ltd. This is not investment advice and should not be interpreted as a recommendation to buy, sell, or hold the stock.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Prism Medico and Pharmacy Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PRISMMEDI across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (72.41%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (-0.33%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.40%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-3.20%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-900.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-52.80% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (0.00% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.00% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Low Promoter Commitment (25.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Prism Medico and Pharmacy Ltd Financial Statements
Comprehensive financial data for Prism Medico and Pharmacy Ltd including income statement, balance sheet and cash flow
About PRISMMEDI (Prism Medico and Pharmacy Ltd)
Prism Medico and Pharmacy Ltd is a Non-Banking Financial Company (NBFC) based in India, focused on providing financial solutions tailored for the healthcare and pharmaceutical sect...ors. Originally established in 1985, the company has evolved from its earlier mercantile operations to specialize in the unique financial needs of medical professionals, pharmacies, and healthcare-related businesses. PRISMMEDI's core business involves extending credit and financial products that support the growth and operational efficiency of entities within the medical ecosystem. This includes financing for equipment procurement, infrastructure development, working capital management, and expansion plans for clinics, hospitals, and pharmacies. The company's commitment is to drive advancement within the Indian healthcare industry by facilitating access to capital and resources. PRISMMEDI operates with a deep understanding of the specific financial challenges faced by the medical community. This understanding allows the company to design financial products and services that are not only accessible but also strategically aligned with the long-term goals of its clients. Beyond lending, PRISMMEDI also offers financial advisory services to help its clients navigate complex financial landscapes, optimize their resource allocation, and make informed investment decisions. By taking a holistic approach to financial support, the company strives to be more than just a lender; it aims to be a trusted partner in its clients' success. PRISMMEDI distinguishes itself through specialized domain knowledge and customized service. The company is dedicated to fostering sustainable growth in the healthcare sector by empowering its clients with the necessary financial tools. PRISMMEDI focuses on building long-term relationships, understanding the unique needs of each client and creating customized financial solutions. With its established presence in India and commitment to providing reliable financial services, PRISMMEDI is positioned to play a significant role in the advancement of Indian healthcare. The company continuously explores innovative approaches to address the changing financial needs of the sector and remains dedicated to upholding the highest standards of integrity and ethical conduct in its operations.
Company Details
Key Leadership
PRISMMEDI Share Price: Frequently Asked Questions
What is the current share price of Prism Medico and Pharmacy Ltd (PRISMMEDI)?
As of 30 Mar 2026, 12:04 pm IST, Prism Medico and Pharmacy Ltd share price is ₹25.21. The PRISMMEDI stock has a market capitalisation of ₹11.21 (Cr) on NSE/BSE.
Is PRISMMEDI share price Overvalued or Undervalued?
PRISMMEDI share price is currently trading at a P/E ratio of 18.38x, compared to the industry average of 22.03x. Based on this relative valuation, the Prism Medico and Pharmacy Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of PRISMMEDI share price?
The 52-week high of PRISMMEDI share price is ₹30.22 and the 52-week low is ₹12.07. These values are updated daily from NSE/BSE price data.
What factors affect the Prism Medico and Pharmacy Ltd share price?
Key factors influencing PRISMMEDI share price include quarterly earnings growth (Sales Growth: 72.41%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Prism Medico and Pharmacy Ltd a good stock for long-term investment?
Prism Medico and Pharmacy Ltd shows a 5-year Profit Growth of 0.00% and an ROE of -0.33%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in PRISMMEDI shares.
How does Prism Medico and Pharmacy Ltd compare with its industry peers?
Prism Medico and Pharmacy Ltd competes with major peers in the Non Banking Financial Company (NBFC). Investors should compare PRISMMEDI share price P/E of 18.38x and ROE of -0.33% against the industry averages to determine competitive standing.
What is the P/E ratio of PRISMMEDI and what does it mean?
PRISMMEDI share price has a P/E ratio of 18.38x compared to the industry average of 22.03x. Investors pay ₹18 for every ₹1 of annual earnings.
How is PRISMMEDI performing according to Bull Run's analysis?
PRISMMEDI has a Bull Run fundamental score of 14.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does PRISMMEDI belong to?
PRISMMEDI operates in the Non Banking Financial Company (NBFC) industry. This classification helps understand the competitive landscape and sector-specific trends affecting Prism Medico and Pharmacy Ltd share price.
What is Return on Equity (ROE) and why is it important for PRISMMEDI?
PRISMMEDI has an ROE of -0.33%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Prism Medico and Pharmacy Ltd generates profits from shareholders capital.
How is PRISMMEDI debt-to-equity ratio and what does it indicate?
PRISMMEDI has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is PRISMMEDI dividend yield and is it a good dividend stock?
PRISMMEDI offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Prism Medico and Pharmacy Ltd shares.
How has PRISMMEDI share price grown over the past 5 years?
PRISMMEDI has achieved 5-year growth rates of: Sales Growth -52.80%, Profit Growth 0.00%, and EPS Growth 0.00%.
What is the promoter holding in PRISMMEDI and why does it matter?
Promoters hold 25.00% of PRISMMEDI shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Prism Medico and Pharmacy Ltd.
What is PRISMMEDI market capitalisation category?
PRISMMEDI has a market capitalisation of ₹11 crores, placing it in the Small-cap category.
How volatile is PRISMMEDI stock?
PRISMMEDI has a beta of N/A. A beta > 1 suggests the Prism Medico and Pharmacy Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is PRISMMEDI operating profit margin trend?
PRISMMEDI has a 5-year average Operating Profit Margin (OPM) of -3.20%, indicating the company's operational efficiency.
How is PRISMMEDI quarterly performance?
Recent quarterly performance shows Prism Medico and Pharmacy Ltd YoY Sales Growth of 72.41% and YoY Profit Growth of -900.00%.
What is the institutional holding pattern in PRISMMEDI?
PRISMMEDI has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Prism Medico and Pharmacy Ltd stock.